Awakn Life Sciences Corp.
AWKN
CNSX
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -87.32% | -56.76% | 70.79% | -95.37% | -93.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -87.32% | -56.76% | 70.79% | -95.37% | -93.42% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -87.32% | -56.76% | 70.79% | -- | -- |
| SG&A Expenses | -44.78% | -69.96% | -43.99% | -43.74% | -32.47% |
| Depreciation & Amortization | -28.26% | 25.93% | 29.63% | 29.63% | 70.37% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.80% | -61.14% | -43.24% | -34.23% | -29.64% |
| Operating Income | 30.46% | 61.22% | 44.70% | 35.88% | 32.53% |
| Income Before Tax | 42.19% | 69.46% | 2.36% | -67.90% | 25.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 42.19% | 69.46% | 2.36% | -67.90% | 25.74% |
| Earnings from Discontinued Operations | -- | -- | -- | 124.61% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.19% | 79.91% | 65.78% | 59.99% | 60.92% |
| EBIT | 30.46% | 61.22% | 44.70% | 35.88% | 32.53% |
| EBITDA | 30.48% | 61.43% | 45.00% | 30.59% | 32.91% |
| EPS Basic | 49.36% | 82.89% | 76.44% | 72.52% | 65.56% |
| Normalized Basic EPS | 50.00% | 78.88% | 8.57% | 8.38% | 34.23% |
| EPS Diluted | 49.36% | 82.89% | 76.44% | 72.52% | 65.56% |
| Normalized Diluted EPS | 50.00% | 78.88% | 8.57% | 8.38% | 34.23% |
| Average Basic Shares Outstanding | 14.96% | 17.99% | 45.08% | 45.60% | 13.35% |
| Average Diluted Shares Outstanding | 14.96% | 17.99% | 45.08% | 45.60% | 13.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |